Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Revenue (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Revenue data on record, last reported at $199.9 million in Q4 2025.

  • For Q4 2025, Revenue fell 5.94% year-over-year to $199.9 million; the TTM value through Dec 2025 reached $1.0 billion, up 28.46%, while the annual FY2025 figure was $1.0 billion, 28.46% up from the prior year.
  • Revenue reached $199.9 million in Q4 2025 per APLS's latest filing, down from $458.6 million in the prior quarter.
  • Across five years, Revenue topped out at $458.6 million in Q3 2025 and bottomed at $623000.0 in Q2 2021.
  • Average Revenue over 5 years is $122.3 million, with a median of $110.4 million recorded in 2023.
  • Peak YoY movement for Revenue: tumbled 75.88% in 2021, then soared 2519.9% in 2022.
  • A 5-year view of Revenue shows it stood at $60.3 million in 2021, then crashed by 62.41% to $22.7 million in 2022, then skyrocketed by 545.89% to $146.4 million in 2023, then surged by 45.19% to $212.5 million in 2024, then dropped by 5.94% to $199.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $199.9 million in Q4 2025, $458.6 million in Q3 2025, and $178.5 million in Q2 2025.